Nautilus Biotechnology, Inc. Debt Securities, Available-for-sale
Nautilus Biotechnology, Inc. (NAUT) had Debt Securities, Available-for-sale of $128.69 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-07-28
- 2026-06-30: Debt Securities, Available-for-sale $128.69M.
- 2026-03-31: Debt Securities, Available-for-sale $142.89M.
- 2025-12-31: Debt Securities, Available-for-sale $155.66M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $128.69M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $142.89M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $155.66M 10-Q · filed 2026-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |